Glioblastoma (GBM) is one of the most prevalent and lethal forms of brain cancer, characterized by rapid growth and a tendency to invade surrounding brain tissue. Despite advances in treatment, the prognosis for GBM remains poor, with a median survival time of approximately 15 months post-diagnosis¹. Antibodies have emerged as a promising tool in the fight against GBM, playing crucial roles in research and development, diagnostics, therapies, and future treatment strategies.

This article explores the promising roles of antibodies in glioblastoma, shedding light on innovative approaches to combat this defying brain cancer.

Research and development

Antibodies are indispensable in glioblastoma research, particularly in identifying and targeting specific antigens expressed by tumor cells. Monoclonal antibodies, identical immune cells cloned from a single parent cell, have been instrumental in this process. Researchers use these antibodies to explore the molecular landscape of GBM, identifying unique biomarkers and potential therapeutic targets².
One significant area of research involves the development of antibody libraries from patient-derived tumorspheres. These libraries enable scientists to screen for antibodies that bind specifically to glioblastoma cells, leading to the identification of novel antigens. For instance, a recent study identified Prostaglandin F2 receptor negative regulator (PTGFRN) as a GBM-specific antigen. Researchers created chimeric antigen receptor (CAR) T-cells targeting PTGFRN, demonstrating significant antitumor activity in preclinical models³.

Diagnostics

Antibodies are also central to the diagnosis of glioblastoma. They are employed in multiple techniques to detect and characterize tumor cells, aiding in accurate diagnosis and treatment planning.

Immunohistochemistry (IHC) is a widely used method in which antibodies bind to specific antigens in tissue sections. This technique helps to identify molecular markers such as IDH1, EGFR, and MGMT, which are critical for glioblastoma classification and prognosis^4,5. IHC provides valuable in situ information, preserving the tumor's histological context.

Flow cytometry uses antibodies to detect and quantify cell surface and intracellular markers in glioblastoma cells6. This method is beneficial for analyzing cell populations and their phenotypic characteristics. For example, spectral flow cytometry can recognize distinct extracellular vesicle phenotypes in glioblastoma patients, offering insights into tumor biology and potential biomarkers for liquid biopsies⁷.

Liquid biopsies involves analyzing circulating tumor cells (CTCs), cell-free DNA (cfDNA), and extracellular vesicles (EVs) in blood or cerebrospinal fluid⁸. Antibodies capture and detect these components, providing non-invasive means to monitor tumor dynamics and treatment response. Liquid biopsies can reveal genetic mutations and molecular alterations, supporting personalized therapy.

Imaging techniques, antibody-based contrast agents enhance techniques such as MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) scans. These agents target specific tumor antigens, improving the visualization of glioblastoma and its boundaries⁹. This approach allows for more precise tumor localization and assessment of treatment efficacy.

Therapies

Antibody-based therapies have revolutionized cancer treatment, and glioblastoma is no exception. Several therapeutic strategies influence the specificity and versatility of antibodies to target GBM cells while sparing healthy tissue.

Immune checkpoint inhibitors: Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block inhibitory signals on immune cells, enhancing immune response against tumors. ICIs targeting programmed cell death protein 1 (PD-1), its ligand PD-L1, and cytotoxic T-lymphocyte antigen 4 (CTLA-4) have shown promise in GBM treatment. These inhibitors release the "brakes" on the immune system, allowing it to attack tumor cells more effectively¹⁰. To learn more about immune checkpoints, explore our Immunotherapy pathway poster here.

Antibody-drug conjugates (ADCs): ADCs are engineered molecules that combine an antibody with a cytotoxic drug. The antibody component binds explicitly to antigens on GBM cells, delivering the cytotoxic payload directly to the tumor. This targeted approach minimizes damage to healthy cells and enhances the therapeutic efficacy. ADCs targeting EGFR and other GBM-specific antigens are currently under investigation¹¹.

CAR T-cell therapy: CAR T-cell therapy involves modifying a patient's T cells to express a chimeric antigen receptor that recognizes and binds to a specific tumor antigen. These engineered T cells are then infused back into the patient, where they seek out and destroy tumor cells¹². CAR T-cell therapy targeting GBM-specific antigens, such as PTGFRN, has shown promising results in preclinical studies³. In addition, a recent report showing the activity of CAR T-cells targeting GAD2 in diffuse intrinsic pontine glioma indicates that responses against primary brain tumors with CAR T-cell therapy are achievable¹³.

Oncolytic virotherapy: This type of therapy uses engineered viruses to infect and kill cancer cells selectively. Antibodies can enhance this therapy by targeting viral particles in glioblastoma cells, increasing the specificity and efficacy of the treatment¹⁴.

B cell-cased vaccines: B cell-based vaccines, such as the BVax, produce antibodies that target GBM cells. These vaccines stimulate the immune system to generate a robust and sustained anti-tumor response. Latest studies have demonstrated that BVax-derived antibodies can inhibit GBM cell migration and invasion, highlighting their therapeutic potential¹⁵.

Future perspectives

Exciting advancements are on the horizon for antibody-based therapies targeting glioblastoma. Researchers are focused on overcoming current challenges to improve treatment outcomes, with several key areas primed for innovative breakthroughs.

Overcoming the blood-brain barrier (BBB): The BBB is a significant obstacle in delivering therapeutic antibodies to the brain. Innovative strategies, such as using nanoparticles or modifying antibodies to enhance BBB penetration, are being explored to improve drug delivery to GBM tumors¹⁶.

Combination therapies: Combining antibody-based therapies with other treatment modalities, such as radiation, chemotherapy, or other immunotherapies, may enhance their efficacy¹⁷. Synergistic effects can overcome resistance mechanisms and improve patient outcomes¹⁸.

Personalized medicine: Advances in genomics and proteomics are paving the way for personalized medicine approaches in GBM treatment. By identifying patient-specific biomarkers and tailoring antibody-based therapies accordingly, clinicians can optimize treatment strategies for individual patients¹⁹.

Novel targets and technologies: Active research continues to identify new GBM-specific antigens and develop innovative antibody-based technologies. Among the promising developments in this field are bispecific antibodies, which can bind to two different antigens simultaneously, and antibody-drug conjugates with enhanced payloads^20,21.

Antibodies play multifaceted roles in the fight against glioblastoma, from advancing research and diagnostics to providing innovative therapeutic options. Although we face challenges, the ongoing exploration of antibody-based solutions is full of promise, offering hope for better outcomes and improved quality of life for those affected by this problematic disease.

References

1.    Sabouri, M.; Dogonchi, A.F.; Shafiei, M.; et al. Survival rate of patient with glioblastoma: a population-based study. Egypt J Neurosurg 39, 42, 2024.
2.    Nakagawa, T.; Kijima, N.; Hasegawa, K.; et al. Identification of glioblastoma-specific antigens expressed in patient-derived tumor cells as candidate targets for chimeric antigen receptor T cell therapy. Neurooncol Adv, 5(1):vdac177, 2022.
3.    Kuroda, H.; Kijima, N.; Nakagawa, K.; et al. 10059- IM-3 Identification of therapeutic target antigens using patient derived glioblastoma and their application to car-t therap. Neurooncol Adv, 29;6(Suppl 4):iv6, 2024.
4.    Jansen M, Yip S, Louis DN. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol, 9(7):717-26, 2010.
5.    Herrera-Oropeza, G.E.; Angulo-Rojo, C.; Gástelum-López, S.A.; et al. Glioblastoma multiforme: a multi-omics analysis of driver genes and tumor heterogeneity. Interface Focus, 11;11(4):20200072, 2021.
6.    Vartholomatos, E.; Vartholomatos, G.; Alexiou, G.A.; et al. The Past, Present and Future of Flow Cytometry in Central Nervous System Malignancies. Methods Protoc, 4, 11, 2021.
7.    Aibaidula, A.Z.; Fain, C.E.; Garcia, L.C.; et al. Spectral flow cytometry identifies distinct nonneoplastic plasma extracellular vesicle phenotype in glioblastoma patients. Neurooncol Adv. 2023 Jul 7;5(1):vdad082
8.    Batool, S.M.; Yekula, A.; Khanna, P.; et al. The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring. Cell Rep Med, 17;4(10):101198, 2023.
9.    Wu, Z.; Dai, L.; Tang, K.; et al. Advances in magnetic resonance imaging contrast agents for glioblastoma-targeting theranostics. Regen Biomater, 12;8(6):rbab062, 2021.
10. Ser, M.H.; Webb, M.J.; Sener, U.; Campian, J.L. Immune Checkpoint Inhibitors, and Glioblastoma: A Review on Current State and Future Directions. J Immunother Precis Oncol, 2;7(2):97-110, 2024.
11. Parakh, S.; Nicolazzo, J.; Scott, A.M.; Gan, H.K. Antibody Drug Conjugates in Glioblastoma - Is There a Future for Them? Front Oncol, 3;11:718590, 2021.
12. Luksik, A.S.; Yazigi, E.; Shah, P.; Jackson, C.M. CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression. Cancers (Basel), 23;15(5):1414, 2023.
13. Majzner, R.G.; Ramakrishna, S.; Yeom, K.W.; et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature, 603(7903):934-941, 2022.
14. Rong, L.; Li, N.; Zhang, Z. Emerging therapies for glioblastoma: current state and future directions. J Exp Clin Cancer Res 41, 142, 2022.
15. Wang, S.; Castro, B.A.; Katz, J.L.; et al. B cell-based therapy produces antibodies that inhibit glioblastoma growth. J Clin Invest. 2024 Aug 29;134(20):e177384.
16. Duan, M.; Cao, R.; Yang, Y.; et al. Blood-Brain Barrier Conquest in Glioblastoma Nanomedicine: Strategies, Clinical Advances, and Emerging Challenges. Cancers (Basel), 27;16(19):3300, 2024.
17. Jain, K.K. A Critical Overview of Targeted Therapies for Glioblastoma. Front Oncol, 15;8:419, 2018.
18. Lara-Velazquez, M.; Shireman, J.M.; Lehrer, E.J.; et al. A Comparison Between Chemo-Radiotherapy Combined With Immunotherapy and Chemo-Radiotherapy Alone for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis. Front Oncol. 2021 May 11;11:662302.
19. Iyer, K.; Saini, S.; Bhadra, S.; Kulavi, S.; Bandyopadhyay, J. Precision medicine advancements in glioblastoma: A systematic review. Biomedicine (Taipei), 1;13(2):1-13, 2023.
20. Wei, J.; Yang, Y.; Wang, G.; Liu, M. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol, 28;13:1035276, 2022.
21. Iurlaro, R.; Waldhauer, I.; Planas-Rigol, E.; et al. A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma. Mol Cancer Ther, 7;21(10):1499-1509, 2022.